What is Benitec Biopharma Inc.'s (BNTC) StockRank?

MoatMap's StockRank for Benitec Biopharma Inc. (BNTC) is 29/100, with a Sell signal. This is a composite score combining Quality (44), Value (39), and Momentum (38) factor ranks across MoatMap's 19,000+ stock universe.

Does Benitec Biopharma Inc. have an economic moat?

Benitec Biopharma Inc. (BNTC) has a Quality factor score of 44/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Benitec Biopharma Inc. a buy, hold, or sell?

MoatMap's current signal for Benitec Biopharma Inc. (BNTC) is Sell, based on a StockRank of 29/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Benitec Biopharma Inc. in?

Benitec Biopharma Inc. (BNTC) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

BNTC

SELLREMOVE

Benitec Biopharma Inc. · Healthcare · United States · $397M · Avg Vol: $996K/d

StockRank

P/E (TTM)

—

ROE

-29.6%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Benitec Biopharma is an early-stage biotech firm with high clinical trial risks and no commercialized products. It lacks the validated, high-utilization CDMO characteristics required to play our healthcare theme.

COMPANY DESCRIPTION

Benitec Biopharma Inc. is a clinical-stage biotechnology company developing genetic medicines based on its proprietary DNA-directed RNA interference (ddRNAi) platform. This technology combines gene therapy with RNA interference to provide sustained, single-administration silencing of disease-causing genes, with a primary focus on treating Oculopharyngeal Muscular Dystrophy (OPMD). Benitec operates as a pioneer in the gene-silencing space, targeting rare genetic diseases with high unmet clinical needs.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	73,000	75,000	0	0	2.7%
EPS	-37.91	-14.12	-1.22	-1.05	—
Shares	480,687	2M	10M	26M	+5361.0%
Debt	811,000	559,000	284,000	849,000	1.5%
Equity	3M	202,000	47M	97M	223.2%
Op CF	-16M	-18M	-19M	-24M	—
Inv CF	-13,000	-1,000	-179,000	-18,000	—
Fin CF	0	16M	68M	70M	—

PRICE (1M)-7.0%

SMA 50SMA 200

$11.33

RSI (14)

48.6

52W High

$17.10

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

-42.7%16.6

ROE

-29.6%25.7

GP/Assets

—N/A

Op. Margin

0.0%40.6

FCF/Assets

-7.2%32.2

Piotroski

—28.8

Int. Cover

—N/A

D/E Ratio

0.00x93.1

Current Ratio

56.82x99.4

Value

P/E (TTM)

—N/A

EV/EBITDA

-4.3x71.5

P/FCF

—N/A

P/B

2.1x53.8

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

66%50.7

RS 6M

-21%54.6

SMA 50/200

0.93x44.0

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-913%0.5

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$397M

P/E (Forward)

-1.2x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BNTC are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
BNTC	Benitec Biopharma Inc.(you)	$397M	29	SELL
GLSI	Greenwich LifeSciences, Inc.	$402M	28	SELL
ENTA	Enanta Pharmaceuticals, Inc.	$385M	28	SELL
STTK	Shattuck Labs, Inc.	$458M	30	SELL
FDMT	4D Molecular Therapeutics, Inc.	$469M	30	SELL
SGMT	Sagimet Biosciences Inc.	$449M	27	SELL
NAUT	Nautilus Biotechnology, Inc.	$330M	33	SELL
PALI	Palisade Bio, Inc.	$358M	35	SELL
ACHV	Achieve Life Sciences, Inc.	$544M	31	SELL
LRMR	Larimar Therapeutics, Inc.	$363M	23	SELL

Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.3%

Benitec Biopharma Inc. (BNTC) — Stock Score Summary

Benitec Biopharma Inc. (BNTC) has a MoatMap StockRank of 29/100 based on Quality (44/100), Value (39/100), and Momentum (38/100) factor scores. The current signal is SELL. Benitec Biopharma is an early-stage biotech firm with high clinical trial risks and no commercialized products. It lacks the validated, high-utilization CDMO characteristics required to play our healthcare theme.

Key Financial Metrics

Price	$11.33
Market Cap	$397M
P/E (Forward)	-1.19
Price/Book	2.09
Return on Equity	-29.6%
Return on Invested Capital	-42.7%
Debt/Equity	0.48
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-7M

Benitec Biopharma Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Benitec Biopharma Inc.’s (BNTC) StockRank?: MoatMap’s StockRank for Benitec Biopharma Inc. (BNTC) is 29/100, with a Sell signal. It is a composite of Quality (44), Value (39), and Momentum (38) factor ranks across MoatMap’s 19,000+ stock universe.
Does Benitec Biopharma Inc. have an economic moat?: Benitec Biopharma Inc. (BNTC) has a Quality factor score of 44/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Benitec Biopharma Inc. a buy, hold, or sell?: MoatMap’s current signal for Benitec Biopharma Inc. (BNTC) is Sell, based on a StockRank of 29/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Benitec Biopharma Inc. in?: Benitec Biopharma Inc. (BNTC) operates in the Healthcare sector, specifically the Biotechnology industry (United States).